Collegium Pharmaceutical (COLL) EBITDA Margin Growth (1y) (2017 - 2026)
Powered by 
Analysis
Collegium Pharmaceutical (COLL) EBITDA Margin Growth (1y) (2017 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 643.26 Bn | 622.50 Bn | 17.26 Bn | 22.00 |
| 2 | AbbVie | 443.31 Bn | 436.74 Bn | 12.70 Bn | 613.00 |
| 3 | Merck | 364.74 Bn | 357.60 Bn | 12.21 Bn | -3,510.00 |
| 4 | Novartis Ag | 266.46 Bn | 258.77 Bn | 11.24 Bn | -164.00 |
| 5 | Pfizer | 158.57 Bn | 146.88 Bn | 10.94 Bn | -611.00 |
| 6 | Sanofi | 52.33 Bn | 44.95 Bn | 10.79 Bn | -572.00 |
| 7 | Revolution Medicines | 43.79 Bn | 43.79 Bn | - | - |
| 8 | Incyte | 25.23 Bn | 20.69 Bn | 1.57 Bn | -194.00 |
| 9 | United Therapeutics | 21.67 Bn | 19.01 Bn | 683.80 Mn | -341.00 |
| 10 | Collegium Pharmaceutical | 753.09 Mn | 603.77 Mn | 110.29 Mn | -1,652.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -1,652.00 |
| Mar 31, 2026 | 339.00 |
| Dec 31, 2025 | 863.00 |
| Sep 30, 2025 | 779.00 |
| Jun 30, 2025 | -1,340.00 |
| Mar 31, 2025 | -2,132.00 |
| Dec 31, 2024 | -2,025.00 |
| Sep 30, 2024 | -1,106.00 |
| Jun 30, 2024 | 639.00 |
| Mar 31, 2024 | 1,713.00 |
| Dec 31, 2023 | 3,284.00 |
| Sep 30, 2023 | 1,681.00 |
| Jun 30, 2023 | 1,730.00 |
| Mar 31, 2023 | 2,897.00 |
| Dec 31, 2022 | 13,306.00 |
| Sep 30, 2022 | -183.00 |
| Jun 30, 2022 | -1,079.00 |
| Mar 31, 2022 | -3,612.00 |
| Dec 31, 2021 | -14,437.00 |
| Sep 30, 2021 | -684.00 |